Evaluating the Oscar Catheter for Treating Peripheral Arterial Disease
Official title: Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries
Run by Biotronik AG · NCT06758921 · Data updated 2026-11-12
This study is testing a new catheter to see if it can safely help people with blocked arteries in their legs feel better after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Biotronik AG Industry-sponsored |
| Locations | 16 sites (Graz and 15 other locations) |
| Status | Recruiting |
| Started | December 19, 2024 |
| Main results expected | December 20, 2025 |
| Study ends | January 20, 2026 |
| Registry record updated | January 6, 2025 |
| Trial ID | NCT06758921 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with significant arterial stenosis and specific Rutherford classifications.
✕Probably not a fit
Patients with less than 70% stenosis or those with certain anatomical restrictions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the safety and clinical performance of the Oscar Peripheral Multifunctional Catheter in patients with lesions in the femoral, popliteal, and infrapopliteal arteries. It will evaluate standard care practices, procedural outcomes, and in-hospital complications associated with endovascular interventions. The primary endpoint focuses on procedural success, defined by successful lesion crossing and minimal residual stenosis, alongside the absence of complications during the procedure.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with Peripheral Arterial Disease by confirming the effectiveness of a new catheter technology.
How similar studies have gone: Previous studies have shown promising results with similar catheter technologies, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subject ≥18 years old 2. Subject has provided written informed consent 3. Subject has Rutherford classification 2 to 6 4. Reference vessel diameter ≥2 and ≤7 mm 5. Target lesion(s) has stenosis \>70% by visual assessment 6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion. Above the knee (ATK) group: 7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau) 8. At least one below-knee artery patent to the ankle 9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications. Below the knee (BTK) group: 10. Target lesions involve arteries below the tibial plateau 11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications Exclusion Criteria: 1. Subject has a single target lesion that involves both ATK and BTK segments. 2. Subject not suitable for receiving endovascular procedures of lower limb arteries. 3. Prior planned major amputation in the target limb (i.e., above the ankle). 4. Subject with previous bypass surgery of target vessel. 5. History of any open surgical procedure within the past 30 days. 6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb. Note: The inflow vessels can be treated on the day of the procedure. 7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis). 8. Subject under dialysis. 9. Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached. 10. Subject lacking capacity to provide informed consent. 11. Subject under judicial protection, tutorship, or curatorship (for France only).
Where it's running
-
LKH Univ. -Klinikum Graz, Ambulanz für Angiologie
Graz, Austria Recruiting -
AZ Saint Blasius
Dendermonde, Belgium Recruiting -
Onze Lieve Vrouwziekenhuis
Aalst, Belgium Not yet recruiting -
ZOL Ziekenhuis Oost Limburg
Genk, Belgium Not yet recruiting -
University Hospital Ghent
Ghent, Belgium Not yet recruiting -
vzw AZ Groeninge
Kortrijk, Belgium Not yet recruiting
Show 10 more locations
-
Hopital Saint Joseph
Paris, France Not yet recruiting -
Karolinen-Hospital Arnsberg
Arnsberg, Germany Not yet recruiting -
Sankt Gertrauden-Krankenhaus
Berlin, Germany Not yet recruiting -
Universitätsklinikum Tübingen
Tübingen, Germany Not yet recruiting -
Semmelweis University
Budapest, Hungary Not yet recruiting -
Policlinico Abano Terme
Abano Terme, Italy Not yet recruiting -
Azienda Usl Toscana sud est
Arezzo, Italy Not yet recruiting -
ospedaliero-universitaria Senese
Siena, Italy Not yet recruiting -
Hospital Universitario de Guadalajara
Guadalajara, Spain Not yet recruiting -
Ospedale Regionale civico EOC di Lugano
Lugano, Switzerland Not yet recruiting
Study contacts
- Principal investigator: Koen Deloose — AZ Saint Blasius
- Study coordinator: Helene Kuissu, PharmD
- Email: helene.kuissu@biotronik.com
- Phone: +41 44 864 54 80
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
Predictors of Major Adverse Limb Events After Iliac Artery Stenting
This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Radial and Ulnar Access in Vascular Interventions Registry
This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.
-
Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease
This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.
-
Imaging plaque activity across the body in people with symptomatic peripheral arterial disease
This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.